The liver is a frequent site of both primary cancer development and metastasis from other tumors. Prometastatic molecular activity in the liver microenvironment can create conditions that allow cancerous cells to thrive and spread. Detecting these changes early is critical for preventing progression and improving treatment outcomes.

The Hepatic Prometastatic Reaction Assay analyzes immune-molecular and prometastatic biomarker activity in the liver environment. This test provides early insight into tumor-promoting conditions, helping clinicians anticipate risk, tailor interventions, and monitor long-term liver-related cancer dynamics.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Hepatic Prometastatic Reaction Assay detects these disruptions at the molecular level so patients and clinicians can act earl

Early Risk Detection

Identifies immune and prometastatic molecular activity in the liver before overt cancer develops.

Precision Oncology Support

Provides evidence for selecting targeted therapy, immunotherapy, or liver-directed treatments.

Monitoring Tool

Tracks progression, recurrence, or treatment effectiveness in patients with hepatic involvement.

Complementary Evidence

Enhances imaging and biopsy findings with immune-molecular context.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Hepatic Prometastatic Reaction Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and liver tumor progression:

  • Angiogenesis and prometastatic factors (VEGF, MMPs, TGF-β)

  • Inflammatory cytokines (IL-6, TNF-α, CRP)

  • Immune checkpoint activity (PD-L1, CTLA-4)

  • Liver microenvironment stress proteins

  • Metabolic and oxidative stress indicators linked to hepatic carcinogenesis

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Register securely through Persona Biomed’s patient portal.

02

Sample Collection

Blood draw at a certified site or via mobile phlebotomy.

03

Laboratory Analysis

Biomarker assays evaluate prometastatic immune and metabolic activity in the liver.

04

Results Delivery

Clinical interpretation report delivered through the portal with physician-ready detail and AI-supported summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with known risk factors for liver cancer (chronic hepatitis, cirrhosis, alcohol-related liver disease).

  • Individuals with existing cancers where liver metastasis risk is high (colorectal, pancreatic, breast).

  • Patients undergoing immunotherapy or targeted therapy requiring molecular monitoring.

  • Survivors of hepatic cancer requiring long-term recurrence surveillance.

Register Now for Hepatic Prometastatic Reaction Assay

Register now for the Hepatic Prometastatic Reaction Assay to uncover molecular signals of liver-related cancer risk and guide precision care.

Register now